US FDA audit of Granules India's Unit V facility results in Zero 483s

Granules India Ltd's Unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India underwent a US FDA inspection from 8th April 2024 to 12th April 2024. This audit was a Pre Approval Inspection (PAI) and cGMP audit for Active Pharmaceutical Ingredients (APIs) and Formulations (FDs); oncology and non-oncology. The audit resulted in Zero 483's.

This facility manufactures APIs & formulations of oncology and non-oncology products.

Shares of Granules India Limited was last trading in BSE at Rs. 421.95 as compared to the previous close of Rs. 426.80. The total number of shares traded during the day was 44131 in over 1655 trades.

The stock hit an intraday high of Rs. 436.10 and intraday low of 421.00. The net turnover during the day was Rs. 18957158.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 USFDA Audit Unit5 Anakapally Visakhapatnam Zero483